{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:23:14Z","timestamp":1788200594703,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":223,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alan Gold Memorial Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The study was conducted to determine the level of ornithine decarboxylase (ODC) activity in several types of peripheral nerve sheath tumors to assess ODC as a potential target for alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ODC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A formalin-fixed paraffin-embedded peripheral nerve sheath tumor tissue microarray was developed in the Department of Anatomic Pathology, MD Anderson Cancer Center. ODC levels were measured using immunofluorescence with a polyclonal antibody to ODC and Alexa-Fluor 647 goat anti-rabbit IgG using previously validated and established methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nuclear and cytoplasmic ODC levels were assessed to determine surrogate ODC activity based on immunofluorescence from 11 patients with a spectrum of nerve sheath tumors, including malignant peripheral nerve sheath tumors (MPNSTs), plexiform neurofibroma, WHO Grade 1 (NF), atypical neurofibroma neoplasm of uncertain biologic potential (ANNUBP), and schwannoma. ODC activity was less than 5 nmol\/30 min\/min\/ug ODC protein in many MPNST, NF, and schwannomas, but higher than 10 nmol\/min\/ug protein in ANNUBP tumors and one NF tumor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nuclear ODC activity varied across peripheral nerve sheath tumors, with relatively low to moderate levels observed in MPNSTs and higher levels in ANNUBP tumors within the small cohort studied. Since DFMO, an irreversible ODC inhibitor, is more effective in slow-growing grade 2 and 3 gliomas with low ODC levels than in higher malignancy grade 4 glioma with high ODC activity, it is reasonable to assume that MPNSTs and neurofibromas, WHO grade, with relatively low to moderate levels of ODC activity may be suitable candidates for DFMO therapy. However, larger studies are needed to validate ODC activity as a predictive biomarker and to determine the therapeutic efficacy of DFMO in peripheral nerve sheath tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag208","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:34:37Z","timestamp":1786448077000},"source":"Crossref","is-referenced-by-count":0,"title":["Ornithine decarboxylase levels in peripheral nerve sheath tumors from NF1 patients"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-2101","authenticated-orcid":false,"given":"Victor A","family":"Levin","sequence":"first","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center , Houston (V.A.L., S.P.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Panchabhai","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center , Houston (V.A.L., S.P.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6144-3233","authenticated-orcid":false,"given":"Rasha","family":"Alfattal","sequence":"additional","affiliation":[{"name":"Department of Pathology and Genomic Medicine, Houston Methodist Hospital , Houston (R.A.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory N","family":"Fuller","sequence":"additional","affiliation":[{"name":"Departments of Anatomic Pathology (Neuropathology) and Neuroradiology, The University of Texas M.D. Anderson Cancer Center , Houston (G.N.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026083113363972700_vdag208-B1","doi-asserted-by":"publisher","first-page":"57171","DOI":"10.18632\/oncotarget.11036","article-title":"Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors","volume":"7","author":"Ahsan","year":"2016","journal-title":"Oncotarget"},{"key":"2026083113363972700_vdag208-B2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00381-020-04731-2","article-title":"Current status of MEK inhibitors in the treatment of plexiform neurofibromas","volume":"36","author":"Gross","year":"2020","journal-title":"Childs Nerv Syst"},{"key":"2026083113363972700_vdag208-B3","doi-asserted-by":"publisher","first-page":"vdaa095","DOI":"10.1093\/noajnl\/vdaa095","article-title":"The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas","volume":"2","author":"Jackson","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2026083113363972700_vdag208-B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072109","article-title":"Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on pediatric brain tumor consortium (PBTC)-029B","volume":"15","author":"Pillay-Smiley","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026083113363972700_vdag208-B5","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"2026083113363972700_vdag208-B6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"2026083113363972700_vdag208-B7","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1158\/1078-0432.CCR-22-2854","article-title":"Combined CDK4\/6 and ERK1\/2 inhibition enhances antitumor activity in NF1-associated plexiform neurofibroma","volume":"29","author":"Flint","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026083113363972700_vdag208-B8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s1471-4914(01)01955-4","article-title":"Tumorigenesis in neurofibromatosis: new insights and potential therapies","volume":"7","author":"Reed","year":"2001","journal-title":"Trends Mol Med"},{"key":"2026083113363972700_vdag208-B9","first-page":"1555","article-title":"Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation","volume":"6","author":"Nishi","year":"1991","journal-title":"Oncogene"},{"key":"2026083113363972700_vdag208-B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/mc.2940060203","article-title":"Alternative splicing of neurofibromatosis type 1 gene transcript in malignant brain tumors: PCR analysis of frozen-section mRNA","volume":"6","author":"Mochizuki","year":"1992","journal-title":"Mol Carcinog"},{"key":"2026083113363972700_vdag208-B11","first-page":"507","article-title":"Ras-GTP levels are elevated in human NF1 peripheral nerve tumors","volume":"12","author":"Guha","year":"1996","journal-title":"Oncogene"},{"key":"2026083113363972700_vdag208-B12","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat Genet"},{"key":"2026083113363972700_vdag208-B13","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0002-9440(10)65507-1","article-title":"Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A\/p16 inactivation","volume":"155","author":"Nielsen","year":"1999","journal-title":"Am J Pathol"},{"key":"2026083113363972700_vdag208-B14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/neuonc\/noae235","article-title":"Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of neurofibromatosis type 1","volume":"27","author":"Lucas","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026083113363972700_vdag208-B15","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1126\/science.286.5447.2172","article-title":"Mouse models of tumor development in neurofibromatosis type 1","volume":"286","author":"Cichowski","year":"1999","journal-title":"Science"},{"key":"2026083113363972700_vdag208-B16","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0002-9440(10)65507-1","article-title":"Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A\/p16 inactivation","volume":"155","author":"Nielsen","year":"1999","journal-title":"Am J Pathol"},{"key":"2026083113363972700_vdag208-B17","first-page":"2748","article-title":"Ornithine decarboxylase induction in transformation by H-Ras and RhoA","volume":"58","author":"Shantz","year":"1998","journal-title":"Cancer Res"},{"key":"2026083113363972700_vdag208-B18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1042\/BJ20030778","article-title":"Transcriptional and translational control of ornithine decarboxylase during Ras transformation","volume":"377","author":"Shantz","year":"2004","journal-title":"Biochem J"},{"key":"2026083113363972700_vdag208-B19","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1158\/0008-5472.CAN-06-4627","article-title":"Ras transformation of RIE-1 cells activates cap-independent translation of ornithine decarboxylase: regulation by the raf\/MEK\/ERK and phosphatidylinositol 3-kinase pathways","volume":"67","author":"Origanti","year":"2007","journal-title":"Cancer Res"},{"key":"2026083113363972700_vdag208-B20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41568-018-0050-3","article-title":"Polyamine metabolism and cancer: treatments, challenges and opportunities","volume":"18","author":"Casero","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2026083113363972700_vdag208-B21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00726-007-0531-2","article-title":"Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential","volume":"33","author":"Shantz","year":"2007","journal-title":"Amino Acids"},{"key":"2026083113363972700_vdag208-B22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/cells9112365","article-title":"Neurofibromin structure, functions and regulation","volume":"9","author":"Bergoug","year":"2020","journal-title":"Cells"},{"key":"2026083113363972700_vdag208-B23","first-page":"981","article-title":"Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas","volume":"9","author":"Levin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026083113363972700_vdag208-B24","first-page":"3878","article-title":"Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme","volume":"6","author":"Levin","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2026083113363972700_vdag208-B25","first-page":"459","article-title":"Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors","volume":"71","author":"Levin","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"2026083113363972700_vdag208-B26","doi-asserted-by":"publisher","first-page":"CNS16","DOI":"10.2217\/cns-2017-0031","article-title":"Clinical importance of eflornithine (alpha-difluoromethylornithine) for the treatment of malignant gliomas","volume":"7","author":"Levin","year":"2018","journal-title":"CNS Oncol"},{"key":"2026083113363972700_vdag208-B27","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/ijc.22914","article-title":"Relationship between tumor ornithine decarboxylase levels and progression-free survival in patients treated with DFMO-PCV chemotherapy","volume":"121","author":"Levin","year":"2007","journal-title":"Int J Cancer"},{"key":"2026083113363972700_vdag208-B28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1369\/jhc.4A6358.2004","article-title":"Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine","volume":"52","author":"Levin","year":"2004","journal-title":"J Histochem Cytochem"},{"key":"2026083113363972700_vdag208-B29","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/ijc.22914","article-title":"Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy","volume":"121","author":"Levin","year":"2007","journal-title":"Int J Cancer"},{"key":"2026083113363972700_vdag208-B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1042\/bj3580025","article-title":"Targeted overexpression of ornithine decarboxylase enhances beta-adrenergic agonist-induced cardiac hypertrophy","volume":"358","author":"Shantz","year":"2001","journal-title":"Biochem J"},{"key":"2026083113363972700_vdag208-B31","first-page":"264","article-title":"Localization of ornithine decarboxylase in mutant CHO cells that overproduce the enzyme. Differences between the intracellular distribution of monospecific ornithine decarboxylase antibodies and radiolabeled alpha-difluoromethylornithine","volume":"35","author":"Anehus","year":"1984","journal-title":"Eur J Cell Biol"},{"key":"2026083113363972700_vdag208-B32","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1091\/mbc.10.12.4299","article-title":"Phosphorylated human keratinocyte ornithine decarboxylase is preferentially associated with insoluble cellular proteins","volume":"10","author":"Pomidor","year":"1999","journal-title":"Mol Biol Cell"},{"key":"2026083113363972700_vdag208-B33","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/j.1471-4159.1985.tb05558.x","article-title":"Involvement of an \u201cantizyme\u201d in the inactivation of ornithine decarboxylase","volume":"45","author":"Laitinen","year":"1985","journal-title":"J Neurochem"},{"key":"2026083113363972700_vdag208-B34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0065-2571(87)90007-0","article-title":"Polyamines in normal and cancer cells","volume":"26","author":"Luk","year":"1987","journal-title":"Adv Enzyme Regul"},{"key":"2026083113363972700_vdag208-B35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0027-5107(93)90136-4","article-title":"Depletion of cellular polyamines by alpha-difluoromethylornithine increases 1,3-bis(2-chloroethyl)-1-nitrosourea-induced sister-chromatid exchanges","volume":"289","author":"Wolff","year":"1993","journal-title":"Mutat Res"},{"key":"2026083113363972700_vdag208-B36","doi-asserted-by":"publisher","first-page":"18757","DOI":"10.1074\/jbc.TM118.003336","article-title":"Polyamine synthesis as a target of MYC oncogenes","volume":"293","author":"Bachmann","year":"2018","journal-title":"J Biol Chem"},{"key":"2026083113363972700_vdag208-B37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1006\/excr.1998.4148","article-title":"Concomitant changes in polyamine pools and DNA methylation during growth inhibition of human colonic cancer cells","volume":"243","author":"Duranton","year":"1998","journal-title":"Exp Cell Res"},{"key":"2026083113363972700_vdag208-B38","doi-asserted-by":"publisher","first-page":"11275","DOI":"10.1093\/nar\/gku837","article-title":"Endogenous polyamine function\u2014the RNA perspective","volume":"42","author":"Lightfoot","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2026083113363972700_vdag208-B39","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/iub.230","article-title":"Mammalian polyamine metabolism and function","volume":"61","author":"Pegg","year":"2009","journal-title":"IUBMB Life"},{"key":"2026083113363972700_vdag208-B40","doi-asserted-by":"publisher","first-page":"14904","DOI":"10.1074\/jbc.R116.731661","article-title":"Functions of polyamines in mammals","volume":"291","author":"Pegg","year":"2016","journal-title":"J Biol Chem"},{"key":"2026083113363972700_vdag208-B41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1200\/JCO-25-01204","article-title":"STELLAR: phase III, randomized, open-label study of eflornithine plus lomustine versus lomustine alone in patients with recurrent grade 3 astrocytoma","volume":"44","author":"Colman","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag208\/70615238\/vdag208.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag208\/70615238\/vdag208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag208\/70615238\/vdag208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:36:42Z","timestamp":1788197802000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag208\/8759257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag208","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag208"}}